| The Clinical Significance of Minimal Change in Reflux Esophagitis Based on the Gastroesophageal Reflux Disease Questionnaire (NCT00901004) | AstraZeneca | 2009-04-01 |
| Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression (NCT00883493) | AstraZeneca | 2009-04-01 |
| Positron Emission Tomography (PET) Study (NCT00886067) | AstraZeneca | 2009-04-01 |
| Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer (NCT00878930) | AstraZeneca | 2009-04-01 |
| A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension (NCT00894322) | AstraZeneca | 2009-04-01 |
| Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes (NCT00859898) | AstraZeneca | 2009-04-01 |
| A 6 Months NIS to Evaluate the Use of Rescue Medication and Quality of Life in Adult Asthmatic Subjects Treated With Symbicort® SMART® (NCT00884689) | AstraZeneca | 2009-04-01 |
| Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33) (NCT00891462) | AstraZeneca | 2009-04-01 |
| Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients (NCT00882518) | AstraZeneca | 2009-04-01 |
| A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart (NCT00887770) | AstraZeneca | 2009-04-01 |
| An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy (NCT00721981) | AstraZeneca | 2009-04-01 |
| Asthma Control and Clinical Practice in Hungary 2009 (NCT00900861) | AstraZeneca | 2009-04-01 |
| Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in France (NCT00812357) | AstraZeneca | 2009-04-01 |
| An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516 (NCT00892944) | AstraZeneca | 2009-04-01 |
| Phase I Multiple Ascending Dose Study for AZD 7268 in Healthy Volunteers (NCT00861718) | AstraZeneca | 2009-04-01 |
| Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC) (NCT00880711) | AstraZeneca | 2009-04-01 |
| Arimidex: Compliance and Arthralgias in Clinical Therapy (COMPACT) (NCT00857012) | AstraZeneca | 2009-04-01 |
| Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia (NCT00873249) | AstraZeneca | 2009-04-01 |
| AZD1981 Midazolam CYP4503A Induction Study (NCT00859352) | AstraZeneca | 2009-03-01 |
| Treatment of Hypertension in Primary Care in Spain (NCT00868881) | AstraZeneca | 2009-03-01 |
| A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS) (NCT00860821) | AstraZeneca | 2009-03-01 |
| Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38) (NCT01045161) | AstraZeneca | 2009-03-01 |
| Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide (NCT00871585) | AstraZeneca | 2009-03-01 |
| Renal Impairment Study (NCT00863161) | AstraZeneca | 2009-03-01 |
| A Study of the Effect of Patient Education (Talking Health Together) in Improving Doctor-patient Communication (NCT00879736) | AstraZeneca | 2009-03-01 |
| Investigation Into the Correlation of Plasma Hs-CRP Concentrations and Cardiovascular Risk in Korean Population (NCT00819273) | AstraZeneca | 2009-03-01 |
| Subjective Well Being of Schizophrenic Patients in Greece (NCT00857064) | AstraZeneca | 2009-03-01 |
| A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin (NCT00870194) | AstraZeneca | 2009-03-01 |
| Bioequivalence Study in Healthy Subjects (NCT00844324) | AstraZeneca | 2009-03-01 |
| Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects (NCT00842556) | AstraZeneca | 2009-03-01 |
| Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation (NCT00867685) | AstraZeneca | 2009-03-01 |
| AZD8566 Food Effect/Microtracer Study (NCT00866385) | AstraZeneca | 2009-03-01 |
| AZD5672 Bioavailability Study in Healthy Male and Female Subjects (NCT00871767) | AstraZeneca | 2009-03-01 |
| A Study to Determine the Effect of Food on the Pharmacokinetics of Oral AZD8931 Tablets (NCT00879346) | AstraZeneca | 2009-03-01 |
| A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5) (NCT00877890) | AstraZeneca | 2009-03-01 |
| Phase I Study to Assess Absorption, Metabolism & Excretion of a Single Oral Dose [14C]AZD0530 in Healthy Male Volunteers (NCT00853983) | AstraZeneca | 2009-03-01 |
| Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Osteoarthritis (OA) of the Knee (NCT00878501) | AstraZeneca | 2009-03-01 |
| Regional Observation of the Metabolic Syndrome (NCT00874952) | AstraZeneca | 2009-03-01 |
| Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients (NCT00868231) | AstraZeneca | 2009-03-01 |
| Pharmacokinetic Study of Daptomycin in Healthy Chinese Subjects Living in China (NCT00858325) | AstraZeneca | 2009-02-01 |
| Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes (NCT00856908) | AstraZeneca | 2009-02-01 |
| AZD9164 Single Ascending Dose Study in Healthy Male Subjects (NCT00847249) | AstraZeneca | 2009-02-01 |
| Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea (NCT02090673) | AstraZeneca | 2009-02-01 |
| Bleeding Time Study With AZD6482, Clopidogrel and ASA (NCT00853450) | AstraZeneca | 2009-02-01 |
| Seroquel XR in Adults With Schizophrenia (NCT00852631) | AstraZeneca | 2009-02-01 |
| Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes (NCT00855166) | AstraZeneca | 2009-02-01 |
| Study to Investigate the Efficacy of Symbicort® SMART. (NCT00839800) | AstraZeneca | 2009-02-01 |
| NIS to Observe Improvement in Global Assessment of Functioning in Patients With Schizophrenia (NCT00833456) | AstraZeneca | 2009-02-01 |
| Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient - a Study in France (NCT00842855) | AstraZeneca | 2009-02-01 |
| Management of Cardiovascular Risk Factors (NCT00848380) | AstraZeneca | 2009-02-01 |
| Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients (NCT00855959) | AstraZeneca | 2009-02-01 |
| Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects (NCT00839683) | AstraZeneca | 2009-02-01 |
| To Evaluate the Response to Glucagon During Hypoglycemia (NCT00817271) | AstraZeneca | 2009-02-01 |
| Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy (NCT00857623) | AstraZeneca | 2009-02-01 |
| Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses (NCT00841048) | AstraZeneca | 2009-02-01 |
| Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551 (NCT00860353) | AstraZeneca | 2009-02-01 |
| AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours (NCT00819221) | AstraZeneca | 2009-01-05 |
| Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin (NCT00817778) | AstraZeneca | 2009-01-01 |
| To Evaluate 24-hr Glucose After OD vs BD AZD1656 (NCT00819884) | AstraZeneca | 2009-01-01 |
| Epidemiological Study to Describe NSCLC Clinical Management Patterns in Europe. Lung-EPICLIN (NCT00831909) | AstraZeneca | 2009-01-01 |
| Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD) (NCT00759395) | AstraZeneca | 2009-01-01 |
| National Survey on GERD Patients (Adults and Children) (NCT00833573) | AstraZeneca | 2009-01-01 |
| Pediatric Bipolar Depression (NCT00811473) | AstraZeneca | 2009-01-01 |
| Investigation of Rate+Extent of Excretion of Radioactivity in Urine+Faeces After Oral Administration of [14C]AZD1386 (NCT00832169) | AstraZeneca | 2009-01-01 |
| Study of Mental Care in Spain (NCT00824031) | AstraZeneca | 2009-01-01 |
| Effect of Multiple Doses of AZD6280 on the Pharmacokinetics of Midazolam (CYP3A4) and Caffeine (CYP1A2) (NCT00824057) | AstraZeneca | 2009-01-01 |
| European Survey of Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB) (NCT00797641) | AstraZeneca | 2009-01-01 |
| Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy (NCT00579150) | AstraZeneca | 2009-01-01 |
| Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD) (NCT00842387) | AstraZeneca | 2009-01-01 |
| Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients (NCT00837967) | AstraZeneca | 2009-01-01 |
| Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066 (NCT00829088) | AstraZeneca | 2009-01-01 |
| Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL (NCT00832221) | AstraZeneca | 2009-01-01 |
| Excretion of Radiolabelled AZD0837 (NCT00812643) | AstraZeneca | 2009-01-01 |
| AZD8075 Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of AZD8075 in Healthy Male Volunteers (NCT00829127) | AstraZeneca | 2009-01-01 |
| Faslodex Post Marketing Surveillance (NCT00860561) | AstraZeneca | 2009-01-01 |
| Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of AZD8566. (NCT00844103) | AstraZeneca | 2009-01-01 |
| Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid (NCT00838877) | AstraZeneca | 2009-01-01 |
| Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium (NCT00808678) | AstraZeneca | 2008-12-01 |
| Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD1446 to Healthy Volunteers (NCT00803855) | AstraZeneca | 2008-12-01 |
| Management of Diabetes Mellitus Patients With Retinopathy (NCT00828425) | AstraZeneca | 2008-12-01 |
| A Feasibility Study to Collect Data in Patients With Haemophilia (NCT00798499) | AstraZeneca | 2008-12-01 |
| To Evaluate the Bioavailability of a Tablet of AZD1656 (NCT00817505) | AstraZeneca | 2008-12-01 |
| National Survey on Hypertension (NCT00804167) | AstraZeneca | 2008-12-01 |
| 14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations (NCT00813306) | AstraZeneca | 2008-12-01 |
| Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017. (NCT00799747) | AstraZeneca | 2008-12-01 |
| Safety, Tolerability, and Pharmacokinetics of AZD7268 After Single Ascending Oral Doses in Healthy Subjects (NCT00796965) | AstraZeneca | 2008-12-01 |
| Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325 (NCT00807937) | AstraZeneca | 2008-12-01 |
| Study to Investigate Safety, Tolerability and PK Following Single and Multiple Ascending Doses of AZD7295 in Japanese (NCT00818129) | AstraZeneca | 2008-12-01 |
| AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD) (NCT00808249) | AstraZeneca | 2008-12-01 |
| Pharmacokinetic Interaction Between AZD3480 and Donepezil (NCT00713765) | AstraZeneca | 2008-12-01 |
| Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects (NCT00785408) | AstraZeneca | 2008-12-01 |
| Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment (NCT00809731) | AstraZeneca | 2008-12-01 |
| Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI) (NCT00944918) | AstraZeneca | 2008-12-01 |
| Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome (NCT00815659) | AstraZeneca | 2008-12-01 |
| Effect of Ketoconazole on Biliary Excretion of AZD0837 (NCT00812344) | AstraZeneca | 2008-12-01 |
| Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients (NCT00782574) | AstraZeneca | 2008-11-12 |
| Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes (NCT00803660) | AstraZeneca | 2008-11-01 |
| To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension (NCT00790153) | AstraZeneca | 2008-11-01 |
| Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients (NCT00789854) | AstraZeneca | 2008-11-01 |
| Hypertensive Treatment Pattern Survey for Type II Diabetes Mellitus Patients With Complication and Hypertension (NCT00771069) | AstraZeneca | 2008-11-01 |